Clinical trial
Expanded Access Study Of BEXXAR® For Low Grade And Transformed Low-Grade…
NCT00268203 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00268203 |
|---|---|
| Title | Expanded Access Study Of BEXXAR® For Low Grade And Transformed Low-Grade Non-Hodgkin's Lymphoma |
| Official title | Expanded Access Study of Iodine I 131 Tositumomab for Relapsed/Refractory Low-Grade and Transformed Low-Grade Non-Hodgkin's Lymphoma |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lymphoma, Non-Hodgkin |
| Intervention type | Biological |
| Interventions | Iodine I 131 Tositumomab Therapeutic Regimen |
| Enrollment | 765 |
| Start date | Sep 1, 1998 |
| Primary completion | Mar 1, 2000 |
| Completion | Feb 1, 2013 |
| First posted | Dec 22, 2005 |
| Last update posted | Jan 9, 2017 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: